STOCK TITAN

Becton Dickinson & Co - BDX STOCK NEWS

Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.

Overview

Becton, Dickinson and Company (BD) is a global medical technology enterprise with decades of expertise in developing, manufacturing, and distributing an extensive range of medical supplies, devices, and diagnostic products. By combining innovation with operational excellence, BD provides critical solutions that are central to patient care, medical discovery, and diagnostic accuracy. Keywords such as medical discovery, diagnostic solutions, and clinical efficiency serve as a testament to its commitment to advancing healthcare across the globe.

Business Model and Core Operations

BD operates through a diversified business model that spans three key segments:

  • BD Medical: Focused on the development and manufacturing of essential surgical products such as needles, syringes, sharps-disposal units, prefilled drug delivery systems, and medication management solutions.
  • BD Life Sciences: Provides state-of-the-art diagnostic instruments, laboratory equipment, reagents, and flow cytometry systems essential for clinical diagnostics and research applications.
  • BD Interventional: Specializes in innovative interventional devices and systems that support surgical procedures and advanced patient monitoring.

The company generates revenue by designing high-quality products for healthcare institutions, physicians, and researchers worldwide, ensuring that each solution meets the rigorous demands of clinical environments and laboratory settings.

Market Position and Competitive Landscape

Positioned as a major player in the medical technology industry, BD stands out for its robust portfolio and widespread market presence. Its commitment to quality, backed by stringent manufacturing and regulatory standards, ensures that its products remain at the forefront of healthcare innovation. In a competitive landscape, BD leverages its diverse product lines and deep industry expertise to address both mature markets and emerging growth areas, balancing reliability with technological advancement.

Technological Innovation and Quality Assurance

Innovation lies at the heart of BD’s operations. The company consistently integrates automation, robotics, and advanced digital technologies into its product lines to enhance workflow efficiency and diagnostic precision. Technological innovation is coupled with rigorous quality assurance processes that adhere to international regulatory standards, ensuring that every product provides reliable performance and safety in critical healthcare settings.

Global Reach and Operational Excellence

With manufacturing facilities and distribution networks spanning multiple countries, BD maintains a resilient supply chain that supports its global operations. A significant emphasis on domestic manufacturing reinforces the stability and reliability of essential medical products, ensuring that healthcare providers receive consistent support and that production remains robust amid industry challenges.

Conclusion

Becton, Dickinson and Company embodies the principles of innovation, quality, and operational excellence in the medical technology industry. Its comprehensive portfolio—from surgical supplies and diagnostic instruments to advanced interventional devices—demonstrates a commitment to enhancing clinical outcomes and supporting medical professionals around the world. This detailed overview reflects BD’s unwavering dedication to advancing healthcare and underscores its significant role in global patient care and medical research.

Rhea-AI Summary

BD (NYSE: BDX) announced key executive appointments effective January 1, 2021. Patrick Kaltenbach is named executive vice president and chief technology officer, succeeding John DeFord, who will retire. Kaltenbach, with nearly 30 years of R&D management experience, will drive BD's innovation strategy and oversee the 'Innovation and Growth Fund.' Additionally, Dave Hickey is promoted to executive vice president and president of the Life Sciences segment, succeeding Kaltenbach. Both leaders will report to CEO Tom Polen, focusing on enhancing BD's impact in medical technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
Rhea-AI Summary

CerTest Biotec and BD (Becton, Dickinson and Company) announced that their VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ System has received CE marking under the IVD Directive (98/79/EC). This kit enables simultaneous testing for COVID-19, Influenza, and RSV, enhancing diagnostic capabilities during flu season. The BD MAX™ System is already used in numerous European laboratories, providing rapid results within two to three hours. BD's collaboration with CerTest aims to improve diagnostic efficiency and patient care during the winter season.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
covid-19
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) celebrates 25 years of partnership with Mercy Ships, announcing a donation of $1 million to support the launch of the Global Mercy, the world's largest NGO hospital ship. This contribution increases BD's total philanthropic investment in Mercy Ships to $2.5 million. The ship, set to sail to Africa in late 2021, features advanced medical facilities and aims to address the severe lack of surgical care, particularly in Africa, where 93% of the 18.6 million annual deaths due to inadequate surgical access occur.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) has received 510(k) clearance from the U.S. FDA for its FACSLyric™ Flow Cytometer combined with the BD FACSDuet™ Sample Preparation System. This integrated system fully automates the sample-to-answer process, enhancing laboratory efficiency by reducing errors and minimizing manual interventions. The FACSDuet provides a walkaway solution that streamlines workflows and improves data integration with laboratory systems. The system is now available as an IVD system in the U.S. and countries recognizing CE-IVD certification.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) announced a live webcast for its fourth fiscal quarter and full fiscal year 2020 earnings conference call on November 5, 2020, at 8:00 a.m. (ET). The earnings press release will precede the call. Investors can access the webcast and related slides on the company's investor website, with a replay available until November 12, 2020. BD operates globally, focusing on advancing health through innovative medical technologies, enhancing care delivery, and supporting health care providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has announced that its SARS-CoV-2 antigen test for the BD Veritor™ Plus System has received CE marking, allowing for commercial availability in Europe by the end of October. This rapid test provides results in just 15 minutes, enhancing COVID-19 diagnostic turnaround times. BD plans to produce 8 million tests per month by October and 12 million by March 2021. The system, already in use for other respiratory conditions, allows simultaneous testing for SARS-CoV-2 and influenza A+B, addressing critical healthcare needs during flu season.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
none
Rhea-AI Summary

On September 23, 2020, BD (Becton, Dickinson and Company) submitted a PMA supplement to the FDA for the ThinPrep® Pap Test™ PreservCyt® Solution vial as an approved sample type for its BD Onclarity™ HPV Assay. This submission aims to expand sample claims beyond the BD SurePath™ vial, providing crucial performance data for BD Viper™ LT and BD COR™ Systems. The company recently received FDA approval for extended genotype reporting, enhancing the assay's capabilities. This commitment underscores BD's focus on improving cervical cancer screening and patient management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has updated the status of its voluntary recalls of the BD Alaris™ System, initiated on August 4, 2020. The FDA classified three recalls as Class I, indicating a significant risk of serious health consequences or death, while one was classified as Class II. The recalls address issues such as unresponsive keypad keys and incorrect module sizes for infusion pumps, potentially leading to delays or inaccuracies in medication delivery. Customers are advised to follow recall instructions provided by BD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) announced a study showing the BD Veritor™ System for Rapid Detection of SARS-CoV-2 is as effective as the Quidel Sofia 2 SARS Antigen Fluorescent Immunoassay. The research involved 361 patient samples, indicating a high agreement in testing accuracy. The BD Veritor™ Plus system showed better correlation with PCR results than its competitor. The study aims to assess performance in community settings and highlights the importance of various factors in understanding antigen assay performance. The findings support the rapid antigen tests' utility in managing COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
covid-19
Rhea-AI Summary

BD (Becton, Dickinson and Company) (NYSE:BDX) announced its participation in upcoming virtual investor healthcare conferences. The company will present at the Wells Fargo Securities 2020 Healthcare Conference on September 10, 2020, at 8:40 a.m. EDT, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 8:45 a.m. EDT. Webcasts of these presentations will be available on their corporate website and can be replayed for seven days post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences

FAQ

What is the current stock price of Becton Dickinson & Co (BDX)?

The current stock price of Becton Dickinson & Co (BDX) is $207.34 as of April 4, 2025.

What is the market cap of Becton Dickinson & Co (BDX)?

The market cap of Becton Dickinson & Co (BDX) is approximately 66.6B.

What are BD's core business segments?

BD operates in three main segments: BD Medical, BD Life Sciences, and BD Interventional, offering a range of products from surgical supplies to diagnostic instruments.

How does BD generate its revenue?

BD generates revenue by developing, manufacturing, and distributing high-quality medical devices and diagnostic products, serving healthcare providers, research institutions, and laboratories globally.

Who are the primary customers of BD?

BD’s products are utilized by hospitals, health systems, physicians, laboratory professionals, and life science researchers to support clinical treatments and diagnostic tests.

How does BD ensure the quality and safety of its products?

BD adheres to stringent quality assurance protocols and international regulatory standards, ensuring that all products meet high safety and performance criteria.

What distinguishes BD in the competitive medtech market?

BD's diverse portfolio, continuous innovation in product design, and robust global manufacturing and distribution capabilities set it apart from competitors.

How is technology integrated into BD’s product development?

The company incorporates cutting-edge automation, robotics, and digital technologies into its equipment and diagnostic tools, enhancing efficiency and accuracy in clinical applications.

What role does global manufacturing play in BD's success?

A strong global manufacturing network ensures a resilient and reliable supply chain, allowing BD to consistently meet the demand for essential medical products around the world.

How does BD support healthcare providers?

BD collaborates with healthcare organizations to tailor solutions that improve clinical outcomes, streamline workflows, and enhance overall patient care across various settings.
Becton Dickinson & Co

NYSE:BDX

BDX Rankings

BDX Stock Data

66.57B
285.49M
0.56%
93.73%
1.02%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
FRANKLIN LAKES